» Articles » PMID: 30092862

Measuring Catastrophic Costs Due to Tuberculosis in Viet Nam

Overview
Specialty Pulmonary Medicine
Date 2018 Aug 11
PMID 30092862
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Progress towards ending tuberculosis (TB) in Viet Nam includes monitoring the costs borne by patients through periodic facility-based surveys.

Objective: To document the magnitude of costs incurred by TB-affected households and establish a baseline for the top End TB indicator in Viet Nam.

Methods: A national survey with retrospective data collection and projection among 735 participants in 20 stratified clusters was conducted in 2016. Each patient was interviewed on costs, time loss, coping measures and asset ownership. Total costs were expressed as a proportion of annual household income.

Results: In Viet Nam, 63% of households affected by TB or multidrug-resistant TB (MDR-TB) experienced costs that were >20% of their annual household income. The mean patient costs were respectively US$1054 and US$4302 per episode of TB and MDR-TB. The most significant drivers of mean costs were income loss reported and purchase of special foods, nutritional supplements, travel and accommodation.

Conclusion: The proportion of households experiencing catastrophic total costs due to TB in Viet Nam is high, which poses a barrier to TB diagnosis and treatment. Based on study results, programme and partners need to identify key areas for policy action and work towards a national policy guide on intervention to reduce TB patient costs.

Citing Articles

Impact of financial support on treatment outcomes of multidrug-resistant tuberculosis: A population-based, retrospective cohort study in Shanghai, China.

Chen Y, Shen X, Zhang Y, Wu Z, Xu B, Chen J J Clin Tuberc Other Mycobact Dis. 2024; 37:100500.

PMID: 39691806 PMC: 11650311. DOI: 10.1016/j.jctube.2024.100500.


Patient costs for drug-resistant TB diagnosis and pre-treatment evaluation in North India.

Das S, Kumar R, Krishnan A, Kant S, Mohan A Public Health Action. 2024; 14(3):129-134.

PMID: 39239156 PMC: 11373743. DOI: 10.5588/pha.24.0018.


TB-related catastrophic costs and associated factors for patients in Ethiopia.

Dememew Z, Deribew A, Datiko D, Melkieneh K, Laloto T, Negash S IJTLD Open. 2024; 1(8):369-371.

PMID: 39131589 PMC: 11308402. DOI: 10.5588/ijtldopen.24.0230.


Determinant of catastrophic costs associated with treatment for rifampicin-resistant TB in households in the Republic of Moldova.

Ciobanu A, Plesca V, Doltu S, Manea M, Domente L, Dadu A IJTLD Open. 2024; 1(6):266-273.

PMID: 39021450 PMC: 11249656. DOI: 10.5588/ijtldopen.23.0608.


Catastrophic costs for tuberculosis patients in India: Impact of methodological choices.

Chatterjee S, Das P, Stallworthy G, Bhambure G, Munje R, Vassall A PLOS Glob Public Health. 2024; 4(4):e0003078.

PMID: 38669225 PMC: 11051603. DOI: 10.1371/journal.pgph.0003078.